Literature DB >> 27182154

Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

Emilio González-Reimers1, Geraldine Quintero-Platt1, Candelaria Martín-González1, Onán Pérez-Hernández1, Lucía Romero-Acevedo1, Francisco Santolaria-Fernández1.   

Abstract

Hepatitis C virus (HCV) infection is associated with increased thrombotic risk. Several mechanisms are involved including direct endothelial damage by the HCV virus, with activation of tissue factor, altered fibrinolysis and increased platelet aggregation and activation. In advanced stages, chronic HCV infection may evolve to liver cirrhosis, a condition in which alterations in the portal microcirculation may also ultimately lead to thrombin activation, platelet aggregation, and clot formation. Therefore in advanced HCV liver disease there is an increased prevalence of thrombotic phenomena in portal vein radicles. Increased thrombin formation may activate hepatic stellate cells and promote liver fibrosis. In addition, ischemic changes derived from vascular occlusion by microthrombi favor the so called parenchymal extinction, a process that promotes collapse of hepatocytes and the formation of gross fibrous tracts. These reasons may explain why advanced HCV infection may evolve more rapidly to end-stage liver disease than other forms of cirrhosis.

Entities:  

Keywords:  Coagulation; Fibrogenesis; Hepatitis C virus; Liver cirrhosis; Parenchymal extinction; Portal thrombosis; Protein C

Mesh:

Substances:

Year:  2016        PMID: 27182154      PMCID: PMC4858626          DOI: 10.3748/wjg.v22.i18.4427

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  94 in total

Review 1.  Advances in understanding pathogenic mechanisms of thrombophilic disorders.

Authors:  Björn Dahlbäck
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

Review 2.  Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis.

Authors:  Xingshun Qi; Weirong Ren; Valerio De Stefano; Daiming Fan
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-30       Impact factor: 11.382

3.  Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis.

Authors:  L E Adinolfi; M G Giordano; A Andreana; M F Tripodi; R Utili; G Cesaro; E Ragone; E Durante Mangoni; G Ruggiero
Journal:  Br J Haematol       Date:  2001-06       Impact factor: 6.998

4.  Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells.

Authors:  M Pinzani; L Gesualdo; G M Sabbah; H E Abboud
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

5.  Endotoxin-induced endothelial fibrosis is dependent on expression of transforming growth factors β1 and β2.

Authors:  César Echeverría; Ignacio Montorfano; Pablo Tapia; Claudia Riedel; Claudio Cabello-Verrugio; Felipe Simon
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

6.  Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis).

Authors:  I R Wanless; J J Liu; J Butany
Journal:  Hepatology       Date:  1995-05       Impact factor: 17.425

7.  Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis.

Authors:  Edoardo Giannini; Paolo Borro; Federica Botta; Alessandra Fumagalli; Federica Malfatti; Elena Podestà; Paola Romagnoli; Emanuela Testa; Bruno Chiarbonello; Simone Polegato; Mario Mamone; Roberto Testa
Journal:  J Hepatol       Date:  2002-11       Impact factor: 25.083

8.  Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus.

Authors:  Ori Wald; Orit Pappo; Rifaat Safadi; Michal Dagan-Berger; Katia Beider; Hanna Wald; Suzanna Franitza; Ido Weiss; Shani Avniel; Pal Boaz; Jacob Hanna; Gidi Zamir; Ahmed Eid; Ofer Mandelboim; Ulrich Spengler; Eithan Galun; Amnon Peled
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

9.  ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.

Authors:  Hendrik B Feys; Maria T Canciani; Flora Peyvandi; Hans Deckmyn; Karen Vanhoorelbeke; Pier M Mannucci
Journal:  Br J Haematol       Date:  2007-06-29       Impact factor: 6.998

Review 10.  Thrombosis Associated with Viral Hepatitis.

Authors:  Luca Galli; Victor E A Gerdes; Luigina Guasti; Alessandro Squizzato
Journal:  J Clin Transl Hepatol       Date:  2014-12-15
View more
  10 in total

1.  Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population.

Authors:  Aki Juhani Käräjämäki; Olli Kettunen; Samuli Lepojärvi; Olli-Pekka Koivurova; Y Antero Kesäniemi; Heikki Huikuri; Olavi Ukkola
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

Review 2.  Hepatitis C virus and cardiovascular: A review.

Authors:  Salvatore Petta
Journal:  J Adv Res       Date:  2016-06-18       Impact factor: 10.479

3.  Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.

Authors:  Haruki Uojima; Shuko Murakami; Seigo Nakatani; Hisashi Hidaka; Atsuko Takeuchi; Yoshiaki Tanaka; Tomoyoshi Inoue; Keiko Yamane; Kousuke Kubota; Takahide Nakazawa; Akitaka Shibuya; Yasuhito Tanaka; Wasaburo Koizumi
Journal:  Intern Med       Date:  2017-12-08       Impact factor: 1.271

4.  Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study.

Authors:  Sergio Salgüero; Luz Maria Medrano; Juan González-García; Juan Berenguer; María L Montes; Cristina Diéz; Pilar Garcia-Broncano; Elba Llop-Herrera; Leire Pérez-Latorre; José María Bellóno; María Ángeles Jiménez-Sousa; Salvador Resino
Journal:  Sci Rep       Date:  2020-06-25       Impact factor: 4.379

Review 5.  Antiviral anticoagulation.

Authors:  Edward L G Pryzdial; Michael R Sutherland; Bryan H Lin; Marc Horwitz
Journal:  Res Pract Thromb Haemost       Date:  2020-07-06

6.  LPS-induced expression and release of monocyte tissue factor in patients with haemophilia.

Authors:  Katharina Holstein; Anna Matysiak; Leonora Witt; Bianca Sievers; Lennart Beckmann; Munif Haddad; Thomas Renné; Minna Voigtlaender; Florian Langer
Journal:  Ann Hematol       Date:  2020-05-19       Impact factor: 3.673

7.  Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study.

Authors:  María Ángeles Jiménez-Sousa; Ana Zaida Gómez-Moreno; Daniel Pineda-Tenor; Juan José Sánchez-Ruano; Tomas Artaza-Varasa; María Martin-Vicente; Amanda Fernández-Rodríguez; Isidoro Martínez; Salvador Resino
Journal:  Biomolecules       Date:  2019-04-09

Review 8.  Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection.

Authors:  Mohammed El-Mowafy; Abdelaziz Elgaml; Mohamed El-Mesery; Salma Sultan; Tamer A E Ahmed; Ahmed I Gomaa; Mahmoud Aly; Walid Mottawea
Journal:  Biology (Basel)       Date:  2021-01-13

9.  Evaluation of Cardiovascular Risk Factors after Hepatitis C Virus Eradication with Direct-Acting Antivirals in a Cohort of Treatment-Naïve Patients without History of Cardiovascular Disease.

Authors:  Diego Casas-Deza; Ana Martínez-Sapiña; Silvia Espina; Beatriz Garcia-Rodriguez; Eva M Fernandez-Bonilla; Alejandro Sanz-Paris; Yolanda Gonzalez-Irazabal; Vanesa Bernal-Monterde; Jose M Arbones-Mainar
Journal:  J Clin Med       Date:  2022-07-13       Impact factor: 4.964

Review 10.  Biology of portal hypertension.

Authors:  Matthew McConnell; Yasuko Iwakiri
Journal:  Hepatol Int       Date:  2017-10-26       Impact factor: 6.047

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.